{"entity":{"id":"nct01503502","kind":"trial","name":"A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","aka":[],"tldr":"A phase 2 trial of Flumatinib and Imatinib in Leukaemia, run by Jiangsu HengRui Medicine Co., Ltd., with a status the registry has not verified recently.","summary":"A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia is a phase 2 interventional study registered as NCT01503502 by Jiangsu HengRui Medicine Co., Ltd., with 150 participants planned, started 2011-08 and due to reach its primary completion in 2012-06. Interventions recorded: flumatinib, imatinib. Conditions recorded: Myelogenous Leukemia, Chronic.\n\nLinked to the drug Flumatinib because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01503502","url":"https://clinicaltrials.gov/study/NCT01503502"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["flumatinib","imatinib"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01503502","phase":"2","setting":"Phase II Study of Flumatinib Versus Imatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","participation":[{"nct":"NCT01503502","source":"https://clinicaltrials.gov/study/NCT01503502","fetchedAt":"2026-10-07T16:52:28.617Z","studySha256":"29dbcf520edcc73eb6dcab5515156e04899813dc2f702459bb285f7d894d192a","overallStatus":"UNKNOWN","lastUpdatePosted":"2013-04-10","leadSponsor":"Jiangsu HengRui Medicine Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":150,"enrolmentType":"ACTUAL","siteCount":5,"recruitingSiteCount":0,"countries":["China"]}],"started":"2011-08","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01503502/","neighbours":{"cancer":[{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"}],"drug":[{"id":"flumatinib","kind":"drug","name":"Flumatinib","route":"/drugs/flumatinib/"},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}